drugset
drugset / Trial / NCT06514963

A Trial of HRS-9813 in Healthy Volunteers

NCT06514963 ↗

Phase 1 Completed 50 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this phase Ⅰ study is to evaluate the safety, tolerability and pharmacokinetics of HRS-9813 in healthy volunteers.

Timeline

Start
2024-07-24
Primary completion
2025-01-02
Completion
2025-01-02

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-9813 Unknown — Oral

Indications

No indication recorded.